Profitelligence Profitelligence · Filing Ledger Open CAH research →

Form 8-K · Current Report · Filed 2024-02-01

Cardinal Health Reports Strong Second Quarter Fiscal 2024 Results and Raises Guidance

Cardinal Health announced its second-quarter fiscal 2024 results, showing a 12% increase in revenue to $57.4 billion.

Filer
Cardinal Health Inc. CAH · NYSE
Filed
Accession
0001628280-24-002805
CIK
0000721371
Signal
High impactHealthcare

Details

Non-GAAP operating earnings rose 20% to $562 million, and non-GAAP diluted EPS increased 38% to $1.82. The company raised its fiscal 2024 non-GAAP EPS guidance to $7.20 to $7.35 and adjusted free cash flow guidance to approximately $2.5 billion. Additionally, Cardinal Health plans to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization.

Items reported

Item 2.02

Results of Operations and Financial Condition

Earnings Beat Raised Guidance
Item 7.01

Regulation FD Disclosure

Regulation FD Disclosure
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$109.19

Next session

-5.2%

Since filing

+110.7%

Latest close

$230.03

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from CAH reporting the same item, with the next session's move:

Exhibits (1)

About Cardinal Health Inc.

Cardinal Health Inc. is a major global healthcare services and products company, distinguished for providing end-to-end medical solutions. Specializing in healthcare distribution and supply chain management, Cardinal Health serves a comprehensive array of clients including hospitals, pharmacies, and healthcare providers. Notably, the company distributes pharmaceuticals, medical products, and laboratory supplies, ensuring efficient delivery to improve healthcare outcomes. Based in Dublin, Ohio, Cardinal Health plays a pivotal role in enhancing healthcare operational efficiency, offering extensive services like inventory management, logistics optimization, and integrated healthcare solutions that empower providers to focus on patient care. As one of the largest pharmaceutical distributors in the United States, it holds substantial influence in the healthcare sector, pivotal in ensuring the availability of drugs and medical supplies across various platforms, contributing significantly to the healthcare infrastructure worldwide.

Exchange NYSE Industry Medical Distribution Company website ↗

Never miss another CAH filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts